MGEN vs. ENZ, PSNL, XGN, DMTK, BDSX, VNRX, CALC, HSAQ, ALGS, and LENZ
Should you be buying Miragen Therapeutics stock or one of its competitors? The main competitors of Miragen Therapeutics include Enzo Biochem (ENZ), Personalis (PSNL), Exagen (XGN), DermTech (DMTK), Biodesix (BDSX), VolitionRx (VNRX), CalciMedica (CALC), Health Sciences Acquisitions Co. 2 (HSAQ), Aligos Therapeutics (ALGS), and LENZ Therapeutics (LENZ). These companies are all part of the "medical" sector.
Enzo Biochem (NYSE:ENZ) and Miragen Therapeutics (NASDAQ:MGEN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, community ranking, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.
36.9% of Enzo Biochem shares are held by institutional investors. 15.5% of Enzo Biochem shares are held by company insiders. Comparatively, 1.1% of Miragen Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, Enzo Biochem and Enzo Biochem both had 1 articles in the media. Miragen Therapeutics' average media sentiment score of 1.00 beat Enzo Biochem's score of 0.00 indicating that Enzo Biochem is being referred to more favorably in the media.
Enzo Biochem has higher revenue and earnings than Miragen Therapeutics.
Enzo Biochem has a net margin of 99.28% compared to Enzo Biochem's net margin of -1,393.50%. Miragen Therapeutics' return on equity of -36.71% beat Enzo Biochem's return on equity.
Enzo Biochem has a beta of 0.75, meaning that its share price is 25% less volatile than the S&P 500. Comparatively, Miragen Therapeutics has a beta of 1.66, meaning that its share price is 66% more volatile than the S&P 500.
Miragen Therapeutics received 55 more outperform votes than Enzo Biochem when rated by MarketBeat users. Likewise, 70.45% of users gave Miragen Therapeutics an outperform vote while only 56.53% of users gave Enzo Biochem an outperform vote.
Summary
Enzo Biochem beats Miragen Therapeutics on 8 of the 12 factors compared between the two stocks.
Get Miragen Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MGEN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Miragen Therapeutics Competitors List
Related Companies and Tools
